Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

VEGF-C as a putative therapeutic target in cancer.

Michaelsen SR, Poulsen HS, Hamerlik P.

Oncotarget. 2019 Jun 18;10(40):3988-3990. doi: 10.18632/oncotarget.27007. eCollection 2019 Jun 18. No abstract available.

2.

Health-related quality of life and caregiver perspectives in glioblastoma survivors: a mixed-methods study.

Piil K, Christensen IJ, Grunnet K, Poulsen HS.

BMJ Support Palliat Care. 2019 Jun 28. pii: bmjspcare-2019-001777. doi: 10.1136/bmjspcare-2019-001777. [Epub ahead of print]

PMID:
31253732
3.

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1270. doi: 10.1074/mcp.W119.001571. No abstract available.

4.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. doi: 10.1074/mcp.RA119.001524.

PMID:
31154438
5.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
6.

Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors.

Johansen MD, Urup T, Holst CB, Christensen IJ, Grunnet K, Lassen U, Friis S, Poulsen HS.

Cancer Invest. 2018;36(9-10):512-519. doi: 10.1080/07357907.2018.1544639.

PMID:
30727779
7.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
8.

Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma.

Lundemann M, Munck Af Rosenschöld P, Muhic A, Larsen VA, Poulsen HS, Engelholm SA, Andersen FL, Kjær A, Larsson HBW, Law I, Hansen AE.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):603-613. doi: 10.1007/s00259-018-4180-3. Epub 2018 Oct 2.

PMID:
30276440
9.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Nov;17(11):2132-2145. doi: 10.1074/mcp.RA118.000792. Epub 2018 Aug 2. Retraction in: Mol Cell Proteomics. 2019 Jun;18(6):1270.

PMID:
30072578
10.

Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.

Galldiks N, Dunkl V, Ceccon G, Tscherpel C, Stoffels G, Law I, Henriksen OM, Muhic A, Poulsen HS, Steger J, Bauer EK, Lohmann P, Schmidt M, Shah NJ, Fink GR, Langen KJ.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2377-2386. doi: 10.1007/s00259-018-4082-4. Epub 2018 Jul 7.

PMID:
29982845
11.

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.

Michaelsen SR, Staberg M, Pedersen H, Jensen KE, Majewski W, Broholm H, Nedergaard MK, Meulengracht C, Urup T, Villingshøj M, Lukacova S, Skjøth-Rasmussen J, Brennum J, Kjær A, Lassen U, Stockhausen MT, Poulsen HS, Hamerlik P.

Neuro Oncol. 2018 Oct 9;20(11):1462-1474. doi: 10.1093/neuonc/noy103.

12.

DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas.

Michaelsen SR, Aslan D, Urup T, Poulsen HS, Grønbæk K, Broholm H, Kristensen LS.

Int J Mol Sci. 2018 Feb 28;19(3). pii: E679. doi: 10.3390/ijms19030679.

13.

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.

Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen VA, Lassen U, Broholm H, Poulsen HS.

Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Review.

PMID:
29393706
14.

Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.

Staberg M, Rasmussen RD, Michaelsen SR, Pedersen H, Jensen KE, Villingshøj M, Skjoth-Rasmussen J, Brennum J, Vitting-Seerup K, Poulsen HS, Hamerlik P.

Mol Oncol. 2018 Mar;12(3):406-420. doi: 10.1002/1878-0261.12174. Epub 2018 Feb 12.

15.

Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.

Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Muhic A, Poulsen HS.

J Neurooncol. 2018 Apr;137(2):439-446. doi: 10.1007/s11060-017-2736-x. Epub 2018 Jan 12.

PMID:
29330749
16.

Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.

Michaelsen SR, Urup T, Olsen LR, Broholm H, Lassen U, Poulsen HS.

J Neurooncol. 2018 May;137(3):533-542. doi: 10.1007/s11060-017-2739-7. Epub 2018 Jan 5.

PMID:
29305787
17.

Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial.

Møller S, Munck Af Rosenschöld P, Costa J, Law I, Poulsen HS, Engelholm SA, Engelholm S.

Radiother Oncol. 2017 Nov;125(2):223-227. doi: 10.1016/j.radonc.2017.09.039. Epub 2017 Oct 17.

PMID:
29054380
18.

Hallmarks of glioblastoma: a systematic review.

Nørøxe DS, Poulsen HS, Lassen U.

ESMO Open. 2017 Feb 22;1(6):e000144. doi: 10.1136/esmoopen-2016-000144. eCollection 2016.

19.

Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.

Malmström A, Poulsen HS, Grønberg BH, Stragliotto G, Hansen S, Asklund T, Holmlund B, Łysiak M, Dowsett J, Kristensen BW, Söderkvist P, Rosell J, Henriksson R; Nordic Clinical Brain Tumor Study Group (NCBTSG).

Acta Oncol. 2017 Dec;56(12):1776-1785. doi: 10.1080/0284186X.2017.1332780. Epub 2017 Jul 4.

PMID:
28675067
20.

Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.

Dahlrot RH, Dowsett J, Fosmark S, Malmström A, Henriksson R, Boldt H, de Stricker K, Sørensen MD, Poulsen HS, Lysiak M, Söderkvist P, Rosell J, Hansen S, Kristensen BW.

Neuropathol Appl Neurobiol. 2018 Feb;44(2):172-184. doi: 10.1111/nan.12415. Epub 2017 Jun 28.

PMID:
28574607
21.

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.

Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbæk M, Toft A, Olsen LR, Jønson L, Issazadeh-Navikas S, Broholm H, Hamerlik P, Poulsen HS, Lassen U.

BMC Cancer. 2017 Apr 18;17(1):278. doi: 10.1186/s12885-017-3251-3.

22.

Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy.

Lundemann M, Costa JC, Law I, Engelholm SA, Muhic A, Poulsen HS, Munck Af Rosenschold P.

Radiother Oncol. 2017 Mar;122(3):380-386. doi: 10.1016/j.radonc.2017.01.002. Epub 2017 Jan 19.

PMID:
28110959
23.

Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial.

Moller S, Law I, Munck Af Rosenschold P, Costa J, Poulsen HS, Engelholm SA, Engelholm S.

Radiother Oncol. 2016 Oct;121(1):132-137. doi: 10.1016/j.radonc.2016.08.014. Epub 2016 Sep 9.

PMID:
27622554
24.

Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.

Staberg M, Michaelsen SR, Rasmussen RD, Villingshøj M, Poulsen HS, Hamerlik P.

Cell Oncol (Dordr). 2017 Feb;40(1):21-32. doi: 10.1007/s13402-016-0301-9. Epub 2016 Oct 20.

PMID:
27766591
25.

The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.

Poulsen SH, Urup T, Grunnet K, Christensen IJ, Larsen VA, Jensen ML, Af Rosenschöld PM, Poulsen HS, Law I.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):373-381. doi: 10.1007/s00259-016-3494-2. Epub 2016 Aug 23.

26.

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.

Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U.

Mol Oncol. 2016 Oct;10(8):1160-8. doi: 10.1016/j.molonc.2016.05.005. Epub 2016 May 26.

27.

Presentation of Two Cases with Early Extracranial Metastases from Glioblastoma and Review of the Literature.

Johansen MD, Rochat P, Law I, Scheie D, Poulsen HS, Muhic A.

Case Rep Oncol Med. 2016;2016:8190950. doi: 10.1155/2016/8190950. Epub 2016 May 9.

28.

Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro.

Staberg M, Michaelsen SR, Olsen LS, Nedergaard MK, Villingshøj M, Stockhausen MT, Hamerlik P, Poulsen HS.

Cancer Cell Int. 2016 Apr 26;16:34. doi: 10.1186/s12935-016-0309-2. eCollection 2016.

29.

A comprehensive profile of recurrent glioblastoma.

Campos B, Olsen LR, Urup T, Poulsen HS.

Oncogene. 2016 Nov 10;35(45):5819-5825. doi: 10.1038/onc.2016.85. Epub 2016 Apr 4. Review.

PMID:
27041580
30.

Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma.

Nedergaard MK, Michaelsen SR, Perryman L, Erler J, Poulsen HS, Stockhausen MT, Lassen U, Kjaer A.

Nucl Med Biol. 2016 Mar;43(3):198-205. doi: 10.1016/j.nucmedbio.2015.12.002. Epub 2015 Dec 22.

31.

Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.

Kristensen LS, Michaelsen SR, Dyrbye H, Aslan D, Grunnet K, Christensen IJ, Poulsen HS, Grønbæk K, Broholm H.

J Neuropathol Exp Neurol. 2016 Mar;75(3):246-55. doi: 10.1093/jnen/nlv024. Epub 2016 Feb 16.

32.

Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.

Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U.

Acta Oncol. 2016;55(4):418-22. doi: 10.3109/0284186X.2015.1114679. Epub 2016 Feb 1.

PMID:
26828563
33.

Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.

Persson M, Nedergaard MK, Brandt-Larsen M, Skovgaard D, Jørgensen JT, Michaelsen SR, Madsen J, Lassen U, Poulsen HS, Kjaer A.

J Nucl Med. 2016 Feb;57(2):272-8. doi: 10.2967/jnumed.115.161703. Epub 2015 Oct 1.

34.

Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience.

Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HBW, Poulsen HS, Law I.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):103-112. doi: 10.1007/s00259-015-3183-6. Epub 2015 Sep 12.

PMID:
26363903
35.

Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging.

Møller S, Lundemann M, Law I, Poulsen HS, Larsson HB, Engelholm SA.

Acta Oncol. 2015;54(9):1521-8. doi: 10.3109/0284186X.2015.1063777. Epub 2015 Jul 23.

PMID:
26203926
36.

18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.

Nedergaard MK, Michaelsen SR, Urup T, Broholm H, El Ali H, Poulsen HS, Stockhausen MT, Kjaer A, Lassen U.

PLoS One. 2015 Feb 13;10(2):e0115315. doi: 10.1371/journal.pone.0115315. eCollection 2015.

37.

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA, Bradner JE, George RE, Gray NS, Young RA, Wong KK.

Cancer Cell. 2014 Dec 8;26(6):909-922. doi: 10.1016/j.ccell.2014.10.019. Erratum in: Cancer Cell. 2015 Jan 12;27(1):149.

38.

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.

Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U.

Cancer Manag Res. 2014 Sep 26;6:373-87. doi: 10.2147/CMAR.S39306. eCollection 2014. Review.

39.

The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts.

Nedergaard MK, Kristoffersen K, Michaelsen SR, Madsen J, Poulsen HS, Stockhausen MT, Lassen U, Kjaer A.

PLoS One. 2014 Jun 11;9(2):e100009. doi: 10.1371/journal.pone.0100009. eCollection 2014.

40.

Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature.

Kristoffersen K, Nedergaard MK, Villingshøj M, Borup R, Broholm H, Kjær A, Poulsen HS, Stockhausen MT.

Cancer Biol Ther. 2014 Jul;15(7):862-77. doi: 10.4161/cbt.28876. Epub 2014 Apr 22.

41.

Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.

Stockhausen MT, Kristoffersen K, Stobbe L, Poulsen HS.

Cancer Biol Ther. 2014 Feb;15(2):216-24. doi: 10.4161/cbt.26736. Epub 2013 Nov 1.

42.

Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.

Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U.

Acta Oncol. 2014 Jul;53(7):939-44. doi: 10.3109/0284186X.2013.879607. Epub 2014 Jan 23.

PMID:
24456504
43.

Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.

Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M, Poulsen HS.

BMC Cancer. 2013 Sep 3;13:402. doi: 10.1186/1471-2407-13-402.

44.

Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures.

Kristoffersen K, Villingshøj M, Poulsen HS, Stockhausen MT.

Cancer Biol Ther. 2013 Jul;14(7):625-37. doi: 10.4161/cbt.24595. Epub 2013 May 10.

45.

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS.

Anticancer Res. 2013 Apr;33(4):1657-60.

PMID:
23564811
46.

Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.

Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U.

J Neurooncol. 2013 Jan;111(2):205-12. doi: 10.1007/s11060-012-1009-y. Epub 2012 Nov 27.

PMID:
23184145
47.

Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines.

Cramer F, Christensen CL, Poulsen TT, Badding MA, Dean DA, Poulsen HS.

Cancer Gene Ther. 2012 Oct;19(10):675-83. doi: 10.1038/cgt.2012.54. Epub 2012 Aug 17.

PMID:
22898898
48.

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells.

Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT, Patterson AV, Poulsen HS.

J Gene Med. 2012 Jul;14(7):445-58. doi: 10.1002/jgm.2630.

PMID:
22576955
49.

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.

Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U.

Acta Oncol. 2012 Jul;51(6):797-804. doi: 10.3109/0284186X.2012.681063. Epub 2012 May 1.

PMID:
22548369
50.

Notch signaling and brain tumors.

Stockhausen MT, Kristoffersen K, Poulsen HS.

Adv Exp Med Biol. 2012;727:289-304. doi: 10.1007/978-1-4614-0899-4_22. Review.

PMID:
22399356

Supplemental Content

Loading ...
Support Center